Pfizer: Surging Cancer Rates Will Boost Revenues


  • Pfizer is expected to experience growth in cancer treatments due to the rising global incidence of cancer, particularly aggressive forms, in young adults.
  • Recent acquisitions, including Seagen and Trillium Therapeutics, have expanded Pfizer’s portfolio of cancer treatments.
  • Despite weak Q1 financials, Pfizer has increased its earnings forecast, plans to invest in R&D, and has a strong cash position.
  • Legal challenges and potential side effects of synthetic uridine in mRNA vaccines pose unquantifiable risks.

Cancer Detection



Just over a year ago I wrote a hit piece on Pfizer Inc. (NYSE:PFE) titled; Don’t Bank On mRNA vaccines. I made the case that the company would fail to reach their revenue targets for their mRNA

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *